- Home
- OPFI vs LXEO Comparison
OPFI vs LXEO Comparison
Compare OPFI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- LXEO
- Stock Information
- Founded
- OPFI 2009
- LXEO 2017
- Country
- OPFI United States
- LXEO United States
- Employees
- OPFI N/A
- LXEO N/A
- Industry
- OPFI Finance: Consumer Services
- LXEO
- Sector
- OPFI Finance
- LXEO
- Exchange
- OPFI Nasdaq
- LXEO Nasdaq
- Market Cap
- OPFI 300.3M
- LXEO 257.0M
- IPO Year
- OPFI N/A
- LXEO 2023
- Fundamental
- Price
- OPFI $10.43
- LXEO $4.72
- Analyst Decision
- OPFI Buy
- LXEO Strong Buy
- Analyst Count
- OPFI 2
- LXEO 7
- Target Price
- OPFI $11.75
- LXEO $15.29
- AVG Volume (30 Days)
- OPFI 1.1M
- LXEO 417.6K
- Earning Date
- OPFI 08-06-2025
- LXEO 08-14-2025
- Dividend Yield
- OPFI 9.60%
- LXEO N/A
- EPS Growth
- OPFI N/A
- LXEO N/A
- EPS
- OPFI N/A
- LXEO N/A
- Revenue
- OPFI $320,831,000.00
- LXEO N/A
- Revenue This Year
- OPFI $113.99
- LXEO N/A
- Revenue Next Year
- OPFI $9.05
- LXEO N/A
- P/E Ratio
- OPFI N/A
- LXEO N/A
- Revenue Growth
- OPFI 31.26
- LXEO N/A
- 52 Week Low
- OPFI $3.93
- LXEO $1.45
- 52 Week High
- OPFI $17.73
- LXEO $12.76
- Technical
- Relative Strength Index (RSI)
- OPFI 40.21
- LXEO 57.71
- Support Level
- OPFI $9.92
- LXEO $4.34
- Resistance Level
- OPFI $11.33
- LXEO $4.99
- Average True Range (ATR)
- OPFI 0.65
- LXEO 0.37
- MACD
- OPFI 0.06
- LXEO 0.01
- Stochastic Oscillator
- OPFI 26.69
- LXEO 67.06
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.